Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 1
1979 5
1980 10
1981 13
1982 12
1983 14
1984 11
1985 2
1986 6
1987 4
1988 8
1989 10
1990 18
1991 20
1992 23
1993 23
1994 27
1995 26
1996 30
1997 23
1998 20
1999 29
2000 21
2001 16
2002 24
2003 30
2004 30
2005 25
2006 23
2007 32
2008 34
2009 31
2010 37
2011 34
2012 41
2013 29
2014 39
2015 36
2016 49
2017 50
2018 48
2019 47
2020 20
Text availability
Article attribute
Article type
Publication date

Search Results

956 results
Results by year
Filters applied: . Clear all
Page 1
Evidence-based clinical practice guidelines for cholelithiasis 2016.
Tazuma S, Unno M, Igarashi Y, Inui K, Uchiyama K, Kai M, Tsuyuguchi T, Maguchi H, Mori T, Yamaguchi K, Ryozawa S, Nimura Y, Fujita N, Kubota K, Shoda J, Tabata M, Mine T, Sugano K, Watanabe M, Shimosegawa T. Tazuma S, et al. J Gastroenterol. 2017 Mar;52(3):276-300. doi: 10.1007/s00535-016-1289-7. Epub 2016 Dec 10. J Gastroenterol. 2017. PMID: 27942871 Review.
Different effects of ursodeoxycholic acid on intrahepatic cholestasis in acute and recovery stages induced by alpha-naphthylisothiocyanate in mice.
Zhang L, Su H, Li Y, Fan Y, Wang Q, Jiang J, Hu Y, Chen G, Tan B, Qiu F. Zhang L, et al. Toxicol Appl Pharmacol. 2018 Mar 1;342:69-78. doi: 10.1016/j.taap.2018.01.019. Epub 2018 Feb 1. Toxicol Appl Pharmacol. 2018. PMID: 29407775
The aim of this study was to determine the effect of ursodeoxycholic acid (UDCA) on the alpha-naphthylisothiocyanate (ANIT)-induced acute and recovery stage of cholestasis model mice. In the acute stage of model mice, pretreatment with UDCA (25, 50, and 100 mgkg(-1) …
The aim of this study was to determine the effect of ursodeoxycholic acid (UDCA) on the alpha-naphthylisothiocyanate (ANIT)-in …
Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy: A meta-analysis (a prisma-compliant study).
Kong X, Kong Y, Zhang F, Wang T, Yan J. Kong X, et al. Medicine (Baltimore). 2016 Oct;95(40):e4949. doi: 10.1097/MD.0000000000004949. Medicine (Baltimore). 2016. PMID: 27749550 Free PMC article. Review.
BACKGROUND: Intrahepatic cholestasis of pregnancy (ICP) is a specific pregnancy-related disorder without standard medical therapies. Ursodeoxycholic acid (UDCA) is the most used medicine, but the efficacy and safety of UDCA remain uncertain. ...UDCA also reduced …
BACKGROUND: Intrahepatic cholestasis of pregnancy (ICP) is a specific pregnancy-related disorder without standard medical therapies. Urso
New Insights on Intrahepatic Cholestasis of Pregnancy.
Floreani A, Gervasi MT. Floreani A, et al. Clin Liver Dis. 2016 Feb;20(1):177-89. doi: 10.1016/j.cld.2015.08.010. Epub 2015 Oct 9. Clin Liver Dis. 2016. PMID: 26593298 Review.
There is an association between ICP and hepatitis C. Current treatment is ursodeoxycholic acid, owing to benefits on pruritus, liver function, safety, and decreased rates of adverse effects....
There is an association between ICP and hepatitis C. Current treatment is ursodeoxycholic acid, owing to benefits on pruritus, …
Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
Carino A, Biagioli M, Marchianò S, Fiorucci C, Zampella A, Monti MC, Scarpelli P, Ricci P, Distrutti E, Fiorucci S. Carino A, et al. Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Oct;1864(10):1422-1437. doi: 10.1016/j.bbalip.2019.07.006. Epub 2019 Jul 17. Biochim Biophys Acta Mol Cell Biol Lipids. 2019. PMID: 31325638
Obeticholic acid (OCA) is a farnesoid-X-receptor (FXR) ligand, shown effective in reducing steatosis and fibrosis in NASH patients. ...Ursodeoxycholic acid (UDCA), is a safe and unexpensive bile acid used in the treatment of liver disorders whose mecha …
Obeticholic acid (OCA) is a farnesoid-X-receptor (FXR) ligand, shown effective in reducing steatosis and fibrosis in NASH patients. . …
Primary biliary cholangitis: Old and novel therapy.
Floreani A, Mangini C. Floreani A, et al. Eur J Intern Med. 2018 Jan;47:1-5. doi: 10.1016/j.ejim.2017.06.020. Epub 2017 Jun 29. Eur J Intern Med. 2018. PMID: 28669591 Review.
The first Food and Drug Administration (FDA)-approved treatment for PBC was ursodeoxycholic acid (UDCA). This treatment slows the progress of the disease, but approximatively 30-40% of patients fail to respond to UDCA. A number of options are under investigation as …
The first Food and Drug Administration (FDA)-approved treatment for PBC was ursodeoxycholic acid (UDCA). This treatment slows …
Systematic review: ursodeoxycholic acid--adverse effects and drug interactions.
Hempfling W, Dilger K, Beuers U. Hempfling W, et al. Aliment Pharmacol Ther. 2003 Nov 15;18(10):963-72. doi: 10.1046/j.1365-2036.2003.01792.x. Aliment Pharmacol Ther. 2003. PMID: 14616161 Free article. Review.
METHODS: A systematic review of the literature was performed using a refined search strategy to evaluate the adverse effects of ursodeoxycholic acid and its interactions with other drugs. RESULTS: Ursodeoxycholic acid caused diarrhoea in …
METHODS: A systematic review of the literature was performed using a refined search strategy to evaluate the adverse effects o …
Therapeutic effects of curcumin and ursodexycholic acid on non-alcoholic fatty liver disease.
Gheibi S, Gouvarchin Ghaleh HE, Motlagh BM, Azarbayjani AF, Zarei L. Gheibi S, et al. Biomed Pharmacother. 2019 Jul;115:108938. doi: 10.1016/j.biopha.2019.108938. Epub 2019 May 6. Biomed Pharmacother. 2019. PMID: 31071511 Free article.
This study was designed to investigate the combinational therapeutic effects of curcumin (CMN) and Ursodeoxycholic acid (UDCA) on non-alcoholic fatty liver disease (NAFLD). ...
This study was designed to investigate the combinational therapeutic effects of curcumin (CMN) and Ursodeoxycholic acid
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Färkkilä M, Schramm C, Spengler U, Chapman R, Bergquist A, Schrumpf E, Nevens F, Trivedi P, Reiter FP, Tornai I, Halilbasic E, Greinwald R, Pröls M, Manns MP, Trauner M; European PSC norUDCA Study Group. Fickert P, et al. J Hepatol. 2017 Sep;67(3):549-558. doi: 10.1016/j.jhep.2017.05.009. Epub 2017 May 18. J Hepatol. 2017. PMID: 28529147 Free article. Clinical Trial.
Similar dose-dependent results were found for secondary endpoints, such as ALT, AST, gamma-GT, or the rate of patients achieving ALP levels <1.5 ULN. Serious adverse events occurred in seven patients in the 500mg/d, five patients in the 1,000mg/d, two patients in the 15 …
Similar dose-dependent results were found for secondary endpoints, such as ALT, AST, gamma-GT, or the rate of patients achieving ALP levels …
Galactosylated Pro-Drug of Ursodeoxycholic Acid: Design, Synthesis, Characterization, and Pharmacological Effects in a Rat Model of Estrogen-Induced Cholestasis.
Di Guida F, Pirozzi C, Magliocca S, Santoro A, Lama A, Russo R, Nieddu M, Burrai L, Boatto G, Mollica MP, Sodano F, Lazzarato L, Chegaev K, Meli R, Raso GM, Rimoli MG. Di Guida F, et al. Mol Pharm. 2018 Jan 2;15(1):21-30. doi: 10.1021/acs.molpharmaceut.7b00626. Epub 2017 Nov 28. Mol Pharm. 2018. PMID: 29140706 Free article.
Ursodeoxycholic acid (UDCA) is considered the first-choice therapy for cholestatic disorders. ...Ethinylestradiol (EE)-induced cholestasis was used to study and compare the effects of UDCAgal with UDCA on bile flow, hepatic canalicular efflux transporter expr
Ursodeoxycholic acid (UDCA) is considered the first-choice therapy for cholestatic disorders. ...Ethinylestradiol (EE)-induced
956 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback